INTRODUCTION: Enzalutamide is a novel antiandrogen which is approved for the treatment of metastatic, castration-resistant prostate cancer (mCRPC) after taxane-based chemotherapy.
The efficacy of enzalutamide after the sequence docetaxel and abiraterone is not proven.
METHODS: Thirty-five mCRPC patients in the German compassionate use program, who received enzalutamide after progression with taxane-based chemotherapy and abiraterone were prospectively evaluated. The endpoints of the study were overall survival, radiologic progression-free survival and safety.
RESULTS: The median treatment duration on enzalutamide was 2.8 months. The median overall survival was 7.5 months (95% confidence interval (CI) 4.7-10.3) while median progression-free survival assessed by imaging was 3.1 months (95% CI 1.4-4.8). The most common toxicities of all grades were anemia and weight loss.
CONCLUSION: Although the results are limited by a small patient number, the consecutive use of enzalutamide and abiraterone after taxane-based chemotherapy shows a modest clinical activity. Thus, sequence therapy alternating between chemotherapy and antihormonal drugs might be a more promising approach in mCRPC treatment.
Written by:
Schmid SC, Geith A, Böker A, Tauber R, Seitz AK, Kuczyk M, von Klot C, Gschwend JE, Merseburger AS, Retz M. Are you the author?
Department of Urology, Technische Universität München, Rechts der Isar Medical Center, Ismaninger Str. 22, 81675, Munich, Germany.
Reference: Adv Ther. 2014 Jan 18. Epub ahead of print.
doi: 10.1007/s12325-014-0092-1
PubMed Abstract
PMID: 24442834
UroToday.com mCRPC Treatment Section
